Alle verbonden artikelen

A transatlantic perspective on the integration of immuno-oncology prognostic and predictive biomarkers in innovative clinical trial design.

Auteurs : Morfouace M, Hewitt SM, Salgado R, Hartmann K, Litiere S, Tejpar S, Golfinopoulos V, Lively T, Thurin M, Conley B, Lacombe D
Jaar : 2018
Journal : Semin Cancer Biol
Volume : 52
Pagina's : 158-165

Network science in clinical trials: A patient-centered approach.

Auteurs : Manem VSK, Salgado R, Aftimos P, Sotiriou C, Haibe-Kains B
Jaar : 2018
Journal : Semin Cancer Biol
Volume : 52
Pagina's : 135-150

Steps forward for cancer precision medicine.

Auteurs : Salgado R, Moore H, Martens JWM, Lively T, Malik S, McDermott U, Michiels S, Moscow JA, Tejpar S, McKee T, Lacombe D
Jaar : 2018
Journal : Nat Rev Drug Discov
Volume : 17(1)
Pagina's : 1-2

Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial.

Auteurs : Buisseret L, Pommey S, Allard B, Garaud S, Bergeron M, Cousineau I, Ameye L, Bareche Y, Paesmans M, Crown JPA, Di Leo A, Loi S, Piccart-Gebhart M, Willard-Gallo K, Sotiriou C, Stagg J
Jaar : 2018
Journal : Ann Oncol
Volume : 29(4)
Pagina's : 1056-62

p-STAT3 in luminal breast cancer: Integrated RNA-protein pooled analysis and results from the BIG 2-98 phase III trial.

Auteurs : Sonnenblick A, Salgado R, Brohée S, Zahavi T, Peretz T, Van den Eynden G, Rouas G, Salmon A, Francis PA, Di Leo A, Crown JPA, Viale G, Daly L, Javdan B, Fujisawa S, de Azambuja E, Ameye L, Piccart-Gebhart M, Bromberg JF, Sotiriou C
Jaar : 2018
Journal : Int J Oncol
Volume : 52(2)
Pagina's : 424-432

Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group o

Auteurs : Dieci MV, Radosevic-Robin N, Fineberg S, Van den Eynden G, Ternes N, Penault-Llorca F, Pruneri G, DAlfonso TM, Demaria S, Castaneda C, Sanchez J, Badve S, Michiels S, Bossuyt V, Rojo F, Singh B, Nielsen T, Viale G, Kim SR, Hewitt S, Wienert S, Loibl S, Rimm D, Symmans F, Denkert C, Adams S, Loi S, Salgado R
Jaar : 2018
Journal : Semin Cancer Biol
Volume : 52
Pagina's : 16-25

Inflammatory Stroma of Lymphoepithelioma-like Carcinoma of the Cervix: Immunohistochemical Study of 3 Cases and Review of the Literature.

Auteurs : Philippe A, Rassy M, Craciun L, Naveaux C, Willard-Gallo K, Larsimont D, Veys I
Jaar : 2018
Journal : Int J Gynecol Pathol
Volume : 37
Pagina's : 482-487

Antigen Specificity and Clinical Significance of IgG and IgA Autoantibodies Produced in situ by Tumor-Infiltrating B Cells in Breast Cancer.

Auteurs : Garaud S, Zayakin P, Buisseret L, Rulle U, Silina K, de Wind A, Van den Eyden G, Larsimont D, Willard-Gallo K
Jaar : 2018
Journal : Front Immunol
Volume : 9
Pagina's : 2660

Cancer immunotherapy-associated hypophysitis.

Auteurs : Solinas C, Porcu M, De Silva P, Musi M, Aspeslagh S, Scartozzi M, Willard-Gallo K, Mariotti S, Saba L
Jaar : 2018
Journal : Semin Oncol
Volume : 45
Pagina's : 181-186

Roadbook for the implementation of next-generation sequencing in clinical practice in oncology and hemato-oncology in Belgium.

Auteurs : Van Valckenborgh E, Hébrant A, Antoniou A, Van Hoof W, Van Bussel J, Pauwels P, Salgado R, Van Doren W, Waeytens A, Van den Bulcke M
Jaar : 2018
Journal : Arch Public Health
Volume : 76
Pagina's : 49

Quantifying Tertiary Lymphoid Structure-Associated Genes in Formalin-Fixed Paraffin-Embedded Breast Cancer Tissues.

Auteurs : Gu-Trantien C, Garaud S, Migliori E, Solinas C, Lodewyckx JN, Willard-Gallo K
Jaar : 2018
Journal : Methods Mol Biol
Volume : 1845
Pagina's : 139-157

Multidisciplinary molecular tumour board: a tool to improve clinical practice and selection accrual for clinical trials in patients with cancer.

Auteurs : Rolfo C, Manca P, Salgado R, Van Dam P, Dendooven A, Machado Coelho A, Ferri Gandia J, Rutten A, Lybaert W, Vermeij J, Gevaert T, Weyn C, Lefebure A, Metsu S, Van Laere S, Peeters M, Pauwels P
Jaar : 2018
Journal : ESMO Open
Volume : 3
Pagina's : e000398

Scoring of tumor-infiltrating lymphocytes: From visual estimation to machine learning.

Auteurs : Klauschen F, Müller KR, Binder A, Bockmayr M, Hägele M, Seegerer P, Wienert S, Pruneri G, de Maria S, Badve S, Michiels S, Nielsen TO, Adams S, Savas P, Symmans F, Willis S, Gruosso T, Park M, Haibe-Kains B, Gallas B, Thompson AM, Cree I, Sotiriou C, Solinas C, Preusser M, Hewitt SM, Rimm D, Viale G, Loi S, Loibl S, Salgado R, Denkert C
Jaar : 2018
Journal : Semin Cancer Biol
Volume : 52
Pagina's : 151-157

Immunity drives TET1 regulation in cancer through NF-?B.

Auteurs : Collignon E, Canale A, Al Wardi C, Bizet M, Calonne E, Dedeurwaerder S, Garaud S, Naveaux C, Barham W, Wilson A, Bouchat S, Hubert P, Van Lint C, Yull F, Sotiriou C, Willard-Gallo K, Noel A, Fuks F
Jaar : 2018
Journal : Sci Adv
Volume : 4
Pagina's : eaap7309

Tumour-infiltrating lymphocytes and the emerging role of immunotherapy in breast cancer.

Auteurs : Luen SJ, Savas P, Fox SB, Salgado R, Loi S
Jaar : 2017
Journal : Pathology
Volume : 49
Pagina's : 141-155

Ovarian Function Suppression in Premenopausal Women with Early-Stage Breast Cancer.

Auteurs : Lambertini M, Del Mastro L, Viglietti G, Pondé NF, Solinas C, de Azambuja E
Jaar : 2017
Journal : Curr Treat Options Oncol
Volume : 18
Pagina's : 4

Tumor infiltrating lymphocytes in gastrointestinal tumors: Controversies and future clinical implications.

Auteurs : Solinas C, Pusole G, Demurtas L, Puzzoni M, Mascia R, Morgan G, Giampieri R, Scartozzi M
Jaar : 2017
Journal : Crit Rev Oncol Hematol
Volume : 110
Pagina's : 106-116

FOXP1 is a key regulator of quiescence in healthy human CD3+ CD4+ T Cells and is constitutively repressed in CD3- CD4+ T cells from patients with lymphoproliferative disorders.

Auteurs : Garaud S, Roufosse F, De Silva P, Gu-Trantien C, Lodewyckx JN, Duvillier H, Dedeurwaerder S, Bizet M, Defrance M, Fuks F, Bex F, Willard-Gallo K
Jaar : 2017
Journal : Eur J Immunol
Volume : 47(1)
Pagina's : 168-179

Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study.

Auteurs : Luen SJ, Salgado R, Fox S, Savas P, Eng-Wong J, Clark E, Kiermaier A, Swain SM, Baselga J, Michiels S, Loi S
Jaar : 2017
Journal : Lancet Oncol
Volume : 18(1)
Pagina's : 52-62

Adjuvant trastuzumab: a 10-year overview of its benefit.

Auteurs : Lambertini M, Pondé NF, Solinas C, de Azambuja E
Jaar : 2017
Journal : Expert Rev Anticancer Ther
Volume : 17
Pagina's : 61-74